Product Type
Antibody
Description
The monoclonal antibody 2952 reacts with a new epitope on C5a (des-Arg), which is formed after the cleavage of C5 into C5a and C5b. C5 participates in the activation of protein pathways in the complement system, which is an important factor in innate immunity. The complement pathway can be divided into activation pathway and lysis pathway. The activation pathway leads to the cleavage of the fifth complement component C5 via C3. C5a induces smooth muscle contraction, increases vascular permeability, causes degranulation of mast cells and basophils, and releases lysosomal enzymes. In addition, C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. Recent studies have shown that by inducing the synthesis of cytokines (such as TNF-αIL-1beta, IL-6 and IL-8), the acute phase response of the liver and the overall immune response can be regulated. General comments: Please note that under given conditions, C5 is known to expose epitopes that are normally only visible in the activated product of cleavage (Reference 5).
Disease
Infectious diseases, Nephrology
Size
100 µg
Immunogen
Infectious diseases
Species
Human
Clonality
Monoclonal
Clone Number
2952
Buffer
PBS, containing 0.1% bovine serum albumin.
Application
Frozen sections, Functional studies, Immuno assays, Western blot
Application Notes
For immunohistology and western blotting, the dilution used depends on the detection system used. It is recommended that users test reagents and determine their own optimal dilution. The typical initial working dilution is 1:50. For functional studies, The in vitro dilution must be optimized in the user's experimental setting. IHC-P: no pretreatment on human tissue sections; antibody used at a concentration of 1μg/mL; human granulocytes with positive control used.
IHC-F: Fix the tissue section in the fixative solution and block it with the specific reagent. Pretreatment with levamisole solution to quench endogenous phosphatase. As a positive control for drusen, but lacking a negative control for the primary antibody.
FS: Antibody 2952 acts as a neutralizing antibody, which can block the interaction between C5a and its receptor. Through a competitive binding study, the antibody was tested for function using U937 cells differentiated with [125I] C5a and Bt2-cAMP. Biological activity can be defined as the ability of the antibody to replace C5a from the surface of U937 cells.
Positive control human granulocytes.
General comments: Please note that under given conditions, C5 is known to expose epitopes that are normally only present in the activated product of cleavage.
Storage Instructions
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
Alternative Names
C5; C5D; C5a; C5b; CPAMD4; ECLZB; complement component 5; complement C5
